Barry Kappel, Sapience Therapeutics CEO
May 31, 2022 10:53 AM EDTUpdated 04:54 PM
Financing
Startups

Pep­tide biotech gets re­newed sup­port from Bris­tol My­ers, oth­ers to bankroll mul­ti­ple on­col­o­gy clin­i­cal pro­grams

Kyle LaHucik

Senior Reporter

The first batch of fi­nanc­ing last­ed about five years, but this time around, Sapi­ence Ther­a­peu­tics thinks its new fund­ing round will have run­way for less …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times